𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bayesian Optimal Design for Phase II Screening Trials

✍ Scribed by Meichun Ding; Gary L. Rosner; Peter Müller

Book ID
109223868
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
985 KB
Volume
64
Category
Article
ISSN
0006-341X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Optimal Bayesian two-phase designs
Optimal Bayesian two-phase designs
✍ Alaattin Erkanli; Refik Soyer; Adrian Angold 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 964 KB

Deparlmetlt ()[ P~3'ehiall 3' and Behacioral Seie~tces, Duke U/literally Aledica/ ('e~ler, Bv~ 3454, I) m'/mm N(' 27710 US I b3,4dnagenlent Science Departing:hi, School ql Business and Puhlic Al, ma~emcli: . \_ 0o%, us, t George Wctshington Lnipersilv. g)~x/liln{ton D(' ~ -~ ~Ccnler /~)r tile Stu@'

Optimal three-stage designs for phase II
Optimal three-stage designs for phase II cancer clinical trials
✍ T. Timothy Chen 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 2 views

The objective of a phase II cancer clinical trial is to screen a treatment that can produce a similar or better response rate compared to the current treatment results. This screening is usually carried out in two stages as proposed by Simon. For ineffective treatment, the trial should terminate at

Optimal flexible designs in phase II cli
Optimal flexible designs in phase II clinical trials
✍ T. Timothy Chen; Tie-Hua Ng 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

In the conduct of a phase II cancer clinical trial, patients usually enter in two stages. If the response rate from the first stage is low, then the study terminates. Within various two-stage designs, Simon proposed the optimal and minimax criteria. In the co-operative group setting, practical consi

Bayesian optimal design for changepoint
Bayesian optimal design for changepoint problems
✍ Juli Atherton; Benoit Charbonneau; David B. Wolfson; Lawrence Joseph; Xiaojie Zh 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 191 KB

## Abstract We investigate Bayesian optimal designs for changepoint problems. We find robust optimal designs which allow for arbitrary distributions before and after the change, arbitrary prior densities on the parameters before and after the change, and any log‐concave prior density on the changep

Bayesian interim analysis of phase II ca
Bayesian interim analysis of phase II cancer clinical trials
✍ Daniel F. Heitjan 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 2 views

Many popular sequential phase II clinical trial designs optimize some criterion subject to constraints on the error probabilities at null and alternative values of the response rate. Such designs may forfeit optimality if one fails to conduct analyses strictly according to plan. Moreover, a decision